Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02614560 (Clinical Trial/ Vadastuximab Talirine)

Study Title

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients (NCT02614560)

Trial Description

This study will examine the safety and anti-leukemic profile of SGN-CD33A (vadastuximab talirine) in patients with relapsed chemo-resistant AML, who are given vadastuximab talirine in combination with standard treatments before a planned stem cell transplant, or vadastuximab talirine alone after a stem cell transplant.

The main purpose of the study is to find the best dose and determine the anti-leukemic activity of vadastuximab talirine, given either pre- or post-allogeneic stem cell transplant (alloSCT) for adults with relapsed or refractory AML. This will be determined by assessing the safety and tolerability of vadastuximab talirine. In addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will be assessed

This trial is sponsored by Seattle Genetics, Inc.

Study Data

  • Condition: Acute Myeloid Leukemia
  • Interventions:
    • Drugs used in this trial
      • Fludarabine
      • Melphalan
      • Methotrexate
      • Tacrolimus
      • vadastuximab talirine
  • Phase: I & II
  • Estimated Enrollment: 102
  • Start: November 2015
  • Estimated Completion: March 2023
  • Last verified: January 2016
  • Last updated: January 2016

Study Schematic

ct2

Click here to Return to Drug map


Last Editorial review: January 22, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar